Pharma Archives - Page 3 of 4 - McAlinden Research Partners

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Markets

Discounted Biotech Sellers, Rich Pharma Buyers May Finally Revive M&A Activity in Healthcare

The acquisition of biotechnology firms is one of the most common ways big pharma replenishes their pipeline of new drugs. However,…

McAlinden Research PartnersMay 12, 2022

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare

Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics

The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…

McAlinden Research PartnersJanuary 4, 2022

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Markets

Biotech, Pharma Cash Piles set to Drive Dealmaking and Buyback Activity in 2022

Most data indicates M&A activity has slowed in the pharmaceutical and biotech industries. However, that may change in 2022 as…

McAlinden Research PartnersDecember 22, 2021

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Markets

AI Promises to Accelerate Drug Discovery, Streamline Biotech Breakthroughs

AI is transforming industries across every sector of the economy. Biotech and pharma are now experiencing a boom in AI initiatives…

McAlinden Research PartnersJuly 27, 2021

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Politics & Policy

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

Encouraging results from recent clinical trials testing the efficacy of using psychedelics like arketamine, LSD, and psilocybin to treat mental…

McAlinden Research PartnersMay 24, 2021

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Markets Services

Depressed Drugstore Stocks Could Get Boost from Industry Makeover

Drugstore chains already faced secular headwinds heading into 2020, as competition from online sellers, independent prescription delivery services, and retail…

McAlinden Research PartnersOctober 19, 2020

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Politics & Policy

While we Await a Vaccine, COVID Therapeutic Developments Could Boost Biotech Stocks

President Trump's bout of COVID-19 launched countless headlines regarding the some of the leading experimental treatments he'd be receiving - therapeutics…

McAlinden Research PartnersOctober 13, 2020

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare

Chinese Healthcare Exports Continue Their COVID Surge

China is ramping up its manufacturing of medical goods, including masks, PPE, and ventilators, as it seeks to ship them…

McAlinden Research PartnersApril 28, 2020

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare

COVID Vaccine Rush Should Raise Concerns

All sizes of pharmaceutical firms from giants like Johnson & Johnson to young guns like Moderna, yet to bring their…

McAlinden Research PartnersApril 1, 2020

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare

Pharma’s First Coronavirus Shortage Comes Sooner than Expected

The FDA and a number of major pharmaceutical firms have warned of drug shortages resulting from chemical plant shut downs…

McAlinden Research PartnersMarch 3, 2020

Pharma

Discounted Biotech Sellers, Rich Pharma Buyers May Finally Revive M&A Activity in Healthcare

Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics

Biotech, Pharma Cash Piles set to Drive Dealmaking and Buyback Activity in 2022

AI Promises to Accelerate Drug Discovery, Streamline Biotech Breakthroughs

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom

Depressed Drugstore Stocks Could Get Boost from Industry Makeover

While we Await a Vaccine, COVID Therapeutic Developments Could Boost Biotech Stocks

Chinese Healthcare Exports Continue Their COVID Surge

COVID Vaccine Rush Should Raise Concerns

Pharma’s First Coronavirus Shortage Comes Sooner than Expected

Joe Mac’s Viewpoint

The Newest Market Insights

Browse by Sector

About Us

Terms & Privacy